Medicines for brain diseases, cancers, and infectious disease
Total Trials
3
As Lead Sponsor
As Collaborator
0
Total Enrollment
239
NCT01348516
Single Ascending Dose (SAD)/Multiple Ascending Dose(MAD) Safety/Pharmacokinetic (PK) Study of KM-023
Phase: Phase 1
Role: Lead Sponsor
Start: May 31, 2011
Completion: Not specified
NCT03022799
Phase I, KM-819 in Healthy Subjects for Parkinson's Disease
Start: Nov 30, 2016
Completion: Nov 30, 2017
NCT05695378
Trial to Evaluate the Efficacy and Safety of KM-819 Treatment to Slow the Progression of Multiple System Atrophy (MSA)
Phase: Phase 2
Start: Feb 27, 2023
Completion: Aug 19, 2024
Loading map...